Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer Inc       

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Pfizer Inc. : Pfizer Gets Positive Opinion from EMA on Leukemia Drug Bosutinib

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/18/2013 | 02:46pm CEST
   By Saabira Chaudhuri 
 

Pfizer Inc. (>> Pfizer Inc.) said the European Medicines Agency (EMA) issued a positive opinion about the conditional marketing authorization of its cancer drug bosutinib in the European Union for the treatment of adult patients with certain types of leukemia.

Pfizer said the positive opinion was adopted by the Committee for Medicinal Products for Human Use and relates to chronic phase, accelerated phase and blast phase Philadelphia chromosome positive chronic myelogenous leukemia previously treated with one or more tyrosine kinase inhibitor and for whom imatinib, nilotinib and dasatinib aren't considered appropriate treatment options.

Conditional approvals in the EU are granted to medicinal products with a positive benefit/risk assessment that address unmet medical needs and whose availability would result in a significant public health benefit.

Bosutinib is an oral, once-daily, kinase inhibitor, which limits cancer cell growth by inhibiting certain signaling pathways.

Pfizer noted that chronic myelogenous leukemia accounts for 15% of all leukemia cases and that, despite the availability of existing treatments for the condition, there remains a need for additional treatment options.

"We believe that bosutinib, if approved by the European Commission, would represent an important option for patients with CML who have progressed on prior treatment and are not candidates for alternative treatments," said Mace Rothenberg, senior vice president of clinical development and medical affairs at the Pfizer Oncology Business Unit. "We believe many doctors and CML patients will find this treatment, if approved, to be a welcome addition, offering a distinct adverse event profile and a convenient once-daily dosing regimen."

Shares were flat at $26.83 in recent premarket trading. The stock has risen 22% in the past 12 months.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Pfizer Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER INC
04:34a Peninsula not giving up on launching new businesses
04:34a American plans bigger planes for Philadelphia service
08/25 PFIZER : Swimming advisory in effect for two Newport News beaches
08/25 PFIZER : Swim advisory lifted for Oceanfront beaches in Virginia Beach
08/25 ASTRAZENECA : to divest part of antibiotics business in up to $1.5 billion deal
08/25 Astra in £1.2bn deal with Pfizer
08/25 PFIZER : AstraZeneca prescribes antibiotics deal for Pfizer
08/25 PFIZER DEAL HIGHLIGHTS US PHARMA TRE : Fitch
08/25DJPFIZER : to Buy Some Of Astra's Antibiotics -- WSJ
08/25 Pfizer snaps up AstraZeneca's antibiotics arm
More news
Sector news : Pharmaceuticals - NEC
08/25 FTSE retreats as pharma stocks fall
08/25DJStocks Fall as Investors Look to Fed's Jackson Hole Meeting
08/25DJStocks Fall as Investors Look to Fed's Jackson Hole Meeting
08/25DJStocks Fall as Investors Look to Fed's Jackson Hole Meeting -- 3rd Update
08/25DJMylan Boosts Price Assistance for EpiPen Amid Backlash
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2015 Update
2015 Antibiotics Stocks To Benefit From 21st Century Cures Act
2015 ISIS PHARMA STOCK DROPS ON GOOD NEWS : Re-Evaluating The Bull Case
2015 DOW DOGS : 14.63% More Returns From 5 Lowest Priced As Of August 6 Per indexArb
2015 Pfizer's GL-2045 an Orphan Drug for CIDP
Advertisement
Financials ($)
Sales 2016 52 871 M
EBIT 2016 19 374 M
Net income 2016 11 351 M
Debt 2016 17 296 M
Yield 2016 3,42%
P/E ratio 2016 19,07
P/E ratio 2017 15,80
EV / Sales 2016 4,32x
EV / Sales 2017 4,09x
Capitalization 211 206 M
More Financials
Chart PFIZER INC
Duration : Period :
Pfizer Inc Technical Analysis Chart | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 39,5 $
Spread / Average Target 13%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
Mikael Dolsten President-Worldwide Research & Development
W. Don Cornwell Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER INC13.96%211 206
JOHNSON & JOHNSON15.57%324 776
ROCHE HOLDING LTD.-11.47%217 694
NOVARTIS AG-9.45%213 882
PFIZER INC.7.87%211 206
MERCK & CO., INC.18.76%173 462
More Results